Gene therapy recipients monitored for 15 years in safety study
NCT ID NCT05713214
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study does not test a new treatment. Instead, it follows 500 people who have already received genetically modified cell therapy for blood cancers. Researchers will check for any delayed side effects over 15 years, as required by the FDA. The goal is to understand long-term risks, not to treat the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy shows promise for myeloma relapse after transplant
- Can a statin tame a cancer protein? early trial seeks answers
- New pill combo shows promise for tough brain cancer
- New antibody drug tested in patients with relapsed blood cancers
- New european effort matches kids with relapsed leukemia to smarter treatments
- New app aims to make End-of-Life conversations easier for cancer patients